Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) have earned a consensus recommendation of "Moderate Buy" from the nine ratings firms that are covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $78.63.
A number of equities research analysts recently weighed in on ENTA shares. Oppenheimer increased their price target on Enanta Pharmaceuticals from $53.00 to $59.00 and gave the company a "market perform" rating in a research note on Wednesday, August 10th. StockNews.com upgraded Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Wednesday, August 10th. Evercore ISI raised Enanta Pharmaceuticals from an "in-line" rating to an "outperform" rating and set a $62.00 price objective on the stock in a report on Wednesday, July 6th. JMP Securities upped their price objective on Enanta Pharmaceuticals from $103.00 to $137.00 and gave the company a "market outperform" rating in a report on Tuesday, August 9th. Finally, Royal Bank of Canada decreased their price objective on Enanta Pharmaceuticals from $67.00 to $66.00 and set a "sector perform" rating on the stock in a report on Tuesday, August 9th.
Get Enanta Pharmaceuticals alerts:Enanta Pharmaceuticals Trading Down 0.1 %
ENTA opened at $52.65 on Friday. Enanta Pharmaceuticals has a 1-year low of $37.59 and a 1-year high of $102.00. The stock's fifty day simple moving average is $60.55 and its 200 day simple moving average is $58.09. The stock has a market cap of $1.09 billion, a PE ratio of -8.98 and a beta of 0.55.
Enanta Pharmaceuticals (NASDAQ:ENTA – Get Rating) last posted its quarterly earnings results on Monday, August 8th. The biotechnology company reported ($1.53) earnings per share for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.17). Enanta Pharmaceuticals had a negative net margin of 134.21% and a negative return on equity of 32.42%. The business had revenue of $19.48 million during the quarter, compared to the consensus estimate of $20.73 million. During the same quarter last year, the company posted ($1.19) EPS. The firm's revenue was down 9.9% on a year-over-year basis. Equities analysts forecast that Enanta Pharmaceuticals will post -5.75 earnings per share for the current year.Hedge Funds Weigh In On Enanta Pharmaceuticals
Large investors have recently bought and sold shares of the company. RA Capital Management L.P. bought a new position in shares of Enanta Pharmaceuticals during the first quarter worth about $68,633,000. State Street Corp raised its position in shares of Enanta Pharmaceuticals by 29.9% during the second quarter. State Street Corp now owns 1,699,428 shares of the biotechnology company's stock worth $80,332,000 after acquiring an additional 390,842 shares during the last quarter. Deep Track Capital LP bought a new stake in Enanta Pharmaceuticals in the first quarter worth approximately $14,146,000. Invesco Ltd. increased its holdings in Enanta Pharmaceuticals by 173.0% in the fourth quarter. Invesco Ltd. now owns 289,844 shares of the biotechnology company's stock worth $21,674,000 after purchasing an additional 183,676 shares in the last quarter. Finally, Darwin Global Management Ltd. bought a new stake in Enanta Pharmaceuticals in the fourth quarter worth approximately $12,428,000. 97.09% of the stock is currently owned by institutional investors.
About Enanta Pharmaceuticals
(Get Rating)
Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.
See Also
- Get a free copy of the StockNews.com research report on Enanta Pharmaceuticals (ENTA)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase's Earnings Say About the Return to the Office?
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.